Showing results (221-230 of 241) with videos related to

Sort By:
Pageof 25
Oncoimmunology|August 21, 2019
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-lineAnna Kreutzman, Bhagwan Yadav, Tim H Brummendorf, et al.
European Journal of Haematology|August 21, 2021
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 studyHjalmar Flygt, Stina Söderlund, Jesper Stentoft, et al.
Cancer Discovery|September 24, 2013
Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemiaTea Pemovska, Mika Kontro, Bhagwan Yadav, et al.
Leukemia|January 26, 2024
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trialHjalmar Flygt, Stina Söderlund, Johan Richter, et al.
Annals of Hematology|April 29, 2023
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effectsInge G P Geelen, Stein-Erik Gullaksen, Mette M Ilander, et al.
Haematologica|April 30, 2025
Different features of acute myeloid leukemia stem cell quantification in intensively treated patientsLok Lam Ngai, Tom Reuvekamp, Diana Hanekamp, et al.
The New England Journal of Medicine|December 8, 2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaBrian J Druker, François Guilhot, Stephen G O'Brien, et al.
Blood|June 28, 2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Michele Baccarani, Michael W Deininger, Gianantonio Rosti, et al.
Blood Advances|July 8, 2018
Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemiaAnne-Sophie Bouillon, Monica S Ventura Ferreira, Shady Adnan Awad, et al.
Leukemia|July 10, 2024
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI TrialFabio Efficace, Francois-Xavier Mahon, Johan Richter, et al.
Pageof 25